Newsroom | Galderma US

Galderma to present new findings from innovative product portfolio at the 2022 VCS Annual Symposium

Galderma Launches EPSOLAY® Cream, a Medical Advance to Treat Bumps and Blemishes of Rosacea

Sol-Gel Technologies and Galderma Announce FDA Approval of EPSOLAY®

Galderma to highlight latest science and innovation across its product portfolio at the 2022 AAD Annual meeting

Galderma Launches TWYNEO® Cream, the First Ever Tretinoin and Benzoyl Peroxide Combination to Treat Facial Acne

Galderma Launches Breakthrough Innovation With ALASTIN Skincare® HA IMMERSE SERUM®

Cetaphil® Champions Sensitive Skin Initiative with an Entire Month of Science-Backed Educational Content

Differin® Joins Forces with Expert Digital Voices to Kickstart the Acne Conversation for Its Fifth-Annual Retinoid Education Week

Galderma Launches Alastin Skincare® ReFORM & RePAIR COMPLEX with TriHex Technology® Designed to Assist with Recovery from Aesthetic Surgical Body Procedures

Galderma successfully completes acquisition of ALASTIN Skincare®

Galderma Receives FDA Approval for New SCULPTRA® Label, Offering More Options to Aesthetic Partners

Galderma announces relocation of U.S. Headquarters to downtown Dallas

Galderma to acquire award-winning ALASTIN Skincare® enhancing its integrated dermatology platform to continue delivering the best experience to patients